FDA OKs First-In-Class Nonopioid Pain Med Suzetrigine

This post was originally published on Medscape

You will shortly be re-directed to the publisher's website

Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective relief of acute pain without the risk of addiction.
Medscape Medical News